Literature DB >> 11535527

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

L A Hazlehurst1, N Valkov, L Wisner, J A Storey, D Boulware, D M Sullivan, W S Dalton.   

Abstract

We previously showed that adhesion of myeloma cells to fibronectin (FN) by means of beta1 integrins causes resistance to certain cytotoxic drugs. The study described here found that adhesion of U937 human histiocytic lymphoma cells to FN provides a survival advantage with respect to damage induced by the topoisomerase (topo) II inhibitors mitoxantrone, doxorubicin, and etoposide. Apoptosis induced by a topo II inhibitor is thought to be initiated by DNA damage. The neutral comet assay was used to determine whether initial drug-induced DNA damage correlated with cellular-adhesion-mediated drug resistance. Cellular adhesion by means of beta1 integrins resulted in a 40% to 60% reduction in mitoxantrone- and etoposide-induced DNA double-strand breaks. When the mechanisms regulating the initial drug-induced DNA damage were examined, a beta1 integrin-mediated reduction in drug-induced DNA double-strand breaks was found to correlate with reduced topo II activity and decreased salt-extractable nuclear topo IIbeta protein levels. Confocal studies showed changes in the nuclear localization of topo IIbeta; however, alterations in the nuclear-to-cytoplasmic ratio of topo IIbeta in FN-adhered cells were not significantly different. Furthermore, after a high level of salt extraction of nuclear proteins, higher levels of topo IIbeta-associated DNA binding were observed in FN-adhered cells than in cells in suspension. Together, these data suggest that topo IIbeta is more tightly bound to the nucleus of FN-adhered cells. Thus, FN adhesion by means of beta1 integrins appears to protect U937 cells from initial drug-induced DNA damage by reducing topo II activity secondarily to alterations in the nuclear distribution of topo IIbeta.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535527     DOI: 10.1182/blood.v98.6.1897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Authors:  Michael F Emmons; Anthony W Gebhard; Rajesh R Nair; Rachid Baz; Mark L McLaughlin; Anne E Cress; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

Review 2.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

3.  RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

4.  Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.

Authors:  Niranjan Yanamandra; Robert W Buzzeo; Mark Gabriel; Lori A Hazlehurst; Yelenis Mari; Darrin M Beaupre; Javier Cuevas
Journal:  J Pharmacol Exp Ther       Date:  2011-03-04       Impact factor: 4.030

5.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

6.  Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms.

Authors:  Faheem M Shaikh; Eric C Seales; William C Clem; Kristin M Hennessy; Ya Zhuo; Susan L Bellis
Journal:  Exp Cell Res       Date:  2008-07-30       Impact factor: 3.905

7.  Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.

Authors:  Pamela S Becker; Kenneth J Kopecky; Adrianne N Wilks; Sylvia Chien; John M Harlan; Cheryl L Willman; Stephen H Petersdorf; Derek L Stirewalt; Thalia Papayannopoulou; Frederick R Appelbaum
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

Review 8.  SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Authors:  Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl
Journal:  World J Urol       Date:  2019-01-25       Impact factor: 4.226

9.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Authors:  Pierre Farmer; Hervé Bonnefoi; Pascale Anderle; David Cameron; Pratyaksha Wirapati; Pratyakasha Wirapati; Véronique Becette; Sylvie André; Martine Piccart; Mario Campone; Etienne Brain; Gaëtan Macgrogan; Thierry Petit; Jacek Jassem; Frédéric Bibeau; Emmanuel Blot; Jan Bogaerts; Michel Aguet; Jonas Bergh; Richard Iggo; Mauro Delorenzi
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

10.  HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.

Authors:  Rajesh R Nair; Michael F Emmons; Anne E Cress; Raul F Argilagos; Kit Lam; William T Kerr; Hong-Gong Wang; William S Dalton; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.